カテゴリ： GlobalData, イスラエル, 企業調査

Teva Pharmaceutical Industries Ltd (TEVA)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Teva Pharmaceutical Industries Ltd (TEVA) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011957
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：146
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company offers generic medicines in a range of dosage forms, including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, as well as active pharmaceutical ingredients (APIs), the essential raw materials to the drug manufacturing industry. It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Market, 2011 to YTD 2017 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deal Details 14
Venture Financing 14
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Partnerships 17
Teva Pharma Enters into Licensing Agreement with Brain Resource 17
Teva Pharma Enters into Agreement with Syqe Medical 18
Teva Pharma Enters into Agreement with Intel 19
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 20
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 21
Teva Pharma Enters into an Agreement with Microchips Biotech 22
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 23
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 24
Equity Offering 25
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 27
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 29
American Well Raises USD10 Million in Private Placement of Shares 31
Debt Offering 32
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 32
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 34
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 36
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 38
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 40
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 42
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 44
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 46
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 48
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 52
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 54
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 56
Asset Transactions 57
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 57
Acquisition 59
Allergan to Sell 10% Stake in Teva Pharma 59
Teva Pharma Sells Stake in Mesoblast 60
Teva Pharma to Acquire Gecko Health Innovations 61
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 62
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 64
Teva Pharma Completes Acquisition of MicroDose Therapeutx 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
Biolin Scientific Acquires Sophion Bioscience 69
Clal Biotech Acquires Stake In TransPharma Medical From Teva 71
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 72
Teva Pharmaceutical Industries Ltd – Key Competitors 74
Teva Pharmaceutical Industries Ltd – Key Employees 75
Teva Pharmaceutical Industries Ltd – Locations And Subsidiaries 76
Head Office 76
Other Locations & Subsidiaries 76
Joint Venture 84
Recent Developments 85
Strategy And Business Planning 85
Oct 26, 2016: Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with Watson 85
Mar 31, 2016: Takeda and Teva Establish “Teva Takeda Yakuhin” in Japan 87
Feb 24, 2016: Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand 88
Financial Announcements 89
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 89
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 93
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 95
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 99
Jan 06, 2017: Teva Provides 2017 Financial Outlook 107
Nov 15, 2016: Teva Reports Third Quarter 2016 Results 109
Aug 04, 2016: Teva Reports Second Quarter 2016 Results 111
May 09, 2016: Teva Reports First Quarter 2016 Results 115
Feb 11, 2016: Teva Reports Full Year 2015 and Fourth Quarter Financial Results 119
Corporate Communications 125
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 125
Sep 19, 2017: Teva Completes Amendment to Credit Facilities 126
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 127
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 129
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 130
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 131
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 132
Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson 134
Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer 136
Jan 25, 2016: Teva Releases Innovation and Social Responsibility Highlights 137
Legal and Regulatory 138
Dec 22, 2016: Teva Reaches Settlement with Government on FCPA 138
Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 139
Other Significant Developments 140
Nov 27, 2017: Teva Announces New Organization Structure and Leadership Changes 140
Nov 21, 2017: Accelerating the Evolution of Pharma’s Digital Landscape – Practices from Viseven 143
Aug 31, 2016: Nanologica and Teva enter into a Feasibility Study Agreement 144
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 145
Appendix 146
Methodology 146
About GlobalData 146
Contact Us 146
Disclaimer 146

List of Tables
Teva Pharmaceutical Industries Ltd, Medical Equipment, Key Facts, 2016 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Year, 2011 to YTD 2017 7
Teva Pharmaceutical Industries Ltd, Medical Equipment Deals By Type, 2011 to YTD 2017 8
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals By Region, 2011 to YTD 2017 9
Teva Pharmaceutical Industries Ltd, Deals By Market, 2011 to YTD 2017 10
Teva Pharmaceutical Industries Ltd, Medical Equipment, Deals Summary, 2011 to YTD 2017 11
Gamida Cell Raises US$10 Million In Series E Financing 14
Teva Pharma Industries Invests In MultiGene Vascular Systems 16
Teva Pharma Enters into Licensing Agreement with Brain Resource 17
Teva Pharma Enters into Agreement with Syqe Medical 18
Teva Pharma Enters into Agreement with Intel 19
MDxHealth Enters into Distribution Agreement with Teva Pharmaceutical 20
Oncotest-Teva Enters into Distribution Agreement with Guardant Health 21
Teva Pharma Enters into an Agreement with Microchips Biotech 22
MDxHealth Enters Into Agreement With Teva Pharma To Commercialize Two Cancer Tests In Israel 23
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 27
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 29
American Well Raises USD10 Million in Private Placement of Shares 31
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 32
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 34
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 36
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 38
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 40
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 42
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 44
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 46
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 48
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 50
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 52
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 54
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 56
CooperSurgical Acquires PARAGARD from Teva Pharma for USD1.1 Billion 57
Allergan to Sell 10% Stake in Teva Pharma 59
Teva Pharma Sells Stake in Mesoblast 60
Teva Pharma to Acquire Gecko Health Innovations 61
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 62
Omron Healthcare To Acquire Minority Stake In Atonomics, Care Diagnostics Company 64
Teva Pharma Completes Acquisition of MicroDose Therapeutx 66
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 67
Biolin Scientific Acquires Sophion Bioscience 69
Clal Biotech Acquires Stake In TransPharma Medical From Teva 71
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 72
Teva Pharmaceutical Industries Ltd, Key Competitors 74
Teva Pharmaceutical Industries Ltd, Key Employees 75
Teva Pharmaceutical Industries Ltd, Subsidiaries 76
Teva Pharmaceutical Industries Ltd, Joint Venture 84

★海外企業調査レポート[Teva Pharmaceutical Industries Ltd (TEVA)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Touchstone Group plc：企業の戦略的SWOT分析
    Touchstone Group plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Carraro Spa：戦略・SWOT・企業財務分析
    Carraro Spa - Strategy, SWOT and Corporate Finance Report Summary Carraro Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The InterTech Group Inc：企業の戦略的SWOT分析
    The InterTech Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Lee Enterprises Inc (LEE)：企業の財務・戦略的SWOT分析
    Lee Enterprises Inc (LEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bloomberg L.P.：企業のM&A・事業提携・投資動向
    Bloomberg L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bloomberg L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Capita plc：企業の戦略・SWOT・財務情報
    Capita plc - Strategy, SWOT and Corporate Finance Report Summary Capita plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Daicel Corp (4202)：企業の財務・戦略的SWOT分析
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Nigerian National Petroleum Corporation：企業の戦略的SWOT分析
    Nigerian National Petroleum Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • StarHub Ltd (CC3)：企業の財務・戦略的SWOT分析
    StarHub Ltd (CC3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vifor Pharma AG：製薬・医療：M&Aディール及び事業提携情報
    Summary Vifor Pharma AG (Vifor Pharma) a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for tre …
  • Anixter International Inc.：企業の戦略・SWOT・財務情報
    Anixter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Anixter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lipocine Inc (LPCN)：企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) operates as a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testoster …
  • Eagle Oil & Gas Co：石油・ガス：M&Aディール及び事業提携情報
    Summary Eagle Oil & Gas Co (Eagle Oil) is an oil and gas company that acquires, develops, regulates, and explores oil and gas reserves. The company offers contract drilling services. It undertakes projects such as Haynesville, Oklahoma stack, West Raymond Field, Marcellus, Woodford, Lower Cotton Val …
  • Midea Group Co Ltd
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Huber+Suhner AG (HUBN)：企業の財務・戦略的SWOT分析
    Huber+Suhner AG (HUBN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Wellcome Trust Sanger Institute-医療機器分野：企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • National Fuel Gas Co (NFG)：企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • SomaLogic Inc：企業の製品パイプライン分析
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …
  • Standex International Corp：企業の戦略・SWOT・財務分析
    Standex International Corp - Strategy, SWOT and Corporate Finance Report Summary Standex International Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • OpGen Inc (OPGN)：企業の財務・戦略的SWOT分析
    OpGen Inc (OPGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆